Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Engage Grants Program

University of British Columbia

$25,000.00

A non-antibiotic alternative to controlling Salmonella infection

EF 2015-16

Résumé
Salmonella infections represent a significant public health concern and disease burden. Significant sources of infection are typically contaminated meat and poultry, eggs, and fresh produce. As such, the control of Salmonella infections in poultry products is one means to reduce human infections. While advances have been made in reducing the frequency of Salmonella contamination in processed poultry, there is mounting pressure on commercial growers to prevent and/or eliminate these pathogens in pre-harvest production facilities. NovoBind Livestock Therapeutics Inc. proposes to develop a novel antibody-based therapeutic strategy that could be provided to commercial growers to prevent and/or eliminate Salmonella pathogens in pre-harvest poultry production facilities. Currently, novel Salmonella-specific antibodies have been generated and are being tested for their efficacy using in vitro cell culture methods. This work capitalizes on the imaging expertise and analytical resources of the University of British Columbia Bioimaging Facility, coupled with their level 2 microbiology capabilities, and complements the expertise of the larger research team, including the antibody development platform offered by Novobind Livestock Therapeutics Inc. This project proposes to: (1) Use advanced light microscopy techniques to analyze and identify, the molecular mechanism of action of NovoBind's neutralizing antibodies against infectious Salmonella. (2) Compare the impact on motility and cellular adherence of antibody-delivered therapeutics versus traditional antibiotic-based therapies currently in use to control Salmonella infection. The development of a Salmonella-selective and highly effective antibody would benefit Canadian and World populations by reducing human infection and illness, loss of life and costs of treatment. The revenue generated by NovoBind in delivering this product would also be an economic boost to Canada.
Programme
Engage Grants Program
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
486931-2015
Name nom
Wasteneys, Geoffrey
Department département
Botany
Organization id
2
Institution établissement
University of British Columbia
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2015
Competition year année de concours
2015
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1554
Committee name en
Pacific Internal Decision Committee
Committee name fr
Comité de décision interne pour le Pacifique
Area of application code
102
Area of application group en
Agriculture and primary food production
Area of application group fr
Agriculture et produits alimentaires primaires
Area of application en
Animal management (animal diseases, breeding)
Area of application fr
Gestion des animaux (maladies animales, reproduction)
Research subject code
5201
Research subject group en
Microbiology
Research subject group fr
Microbiologie
Research subject en
Bacteriology
Research subject fr
Bactériologie
Partie
1
Nb partie
1
Application title
A non-antibiotic alternative to controlling Salmonella infection
Keyword
NSERC
Application summary
Salmonella infections represent a significant public health concern and disease burden. Significant sources of infection are typically contaminated meat and poultry, eggs, and fresh produce. As such, the control of Salmonella infections in poultry products is one means to reduce human infections. While advances have been made in reducing the frequency of Salmonella contamination in processed poultry, there is mounting pressure on commercial growers to prevent and/or eliminate these pathogens in pre-harvest production facilities. NovoBind Livestock Therapeutics Inc. proposes to develop a novel antibody-based therapeutic strategy that could be provided to commercial growers to prevent and/or eliminate Salmonella pathogens in pre-harvest poultry production facilities. Currently, novel Salmonella-specific antibodies have been generated and are being tested for their efficacy using in vitro cell culture methods. This work capitalizes on the imaging expertise and analytical resources of the University of British Columbia Bioimaging Facility, coupled with their level 2 microbiology capabilities, and complements the expertise of the larger research team, including the antibody development platform offered by Novobind Livestock Therapeutics Inc. This project proposes to: (1) Use advanced light microscopy techniques to analyze and identify, the molecular mechanism of action of NovoBind's neutralizing antibodies against infectious Salmonella. (2) Compare the impact on motility and cellular adherence of antibody-delivered therapeutics versus traditional antibiotic-based therapies currently in use to control Salmonella infection. The development of a Salmonella-selective and highly effective antibody would benefit Canadian and World populations by reducing human infection and illness, loss of life and costs of treatment. The revenue generated by NovoBind in delivering this product would also be an economic boost to Canada.